Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vivos Therapeutics (VVOS) Assets (2019 - 2025)

Vivos Therapeutics has reported Assets over the past 7 years, most recently at $25.2 million for Q4 2025.

  • Quarterly Assets rose 64.56% to $25.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $25.2 million through Dec 2025, up 64.56% year-over-year, with the annual reading at $25.2 million for FY2025, 64.56% up from the prior year.
  • Assets was $25.2 million for Q4 2025 at Vivos Therapeutics, down from $25.6 million in the prior quarter.
  • Over five years, Assets peaked at $46.2 million in Q2 2021 and troughed at $10.3 million in Q3 2023.
  • The 5-year median for Assets is $17.8 million (2022), against an average of $21.4 million.
  • Year-over-year, Assets tumbled 59.27% in 2022 and then soared 67.09% in 2025.
  • A 5-year view of Assets shows it stood at $33.7 million in 2021, then tumbled by 59.27% to $13.7 million in 2022, then decreased by 21.79% to $10.7 million in 2023, then skyrocketed by 42.44% to $15.3 million in 2024, then surged by 64.56% to $25.2 million in 2025.
  • Per Business Quant, the three most recent readings for VVOS's Assets are $25.2 million (Q4 2025), $25.6 million (Q3 2025), and $26.0 million (Q2 2025).